home
顺序
主题
题目
日子
46
Elevar Therapeutics announces enrollment of the first patient in a pivotal trial for the treatment of Adenoid Cystic Cancer (AC
admin
 
45
HLB requests marketing authorization for second-line liver cancer for Rivoceranib
admin
 
44
HLB's acquisiton of Rivoceranib's global rights
admin
 
43
HLB takes over Immunomic Therapeutics
admin
 
42
HLB receives Pre-NDA Meeting Minutes from FDA
admin
2019.11.25
41
HLB initiates administration to the first patient in clinical combination study of Colorectal Cancer
admin
2019.11.20
40
HLB completes Pre-NDA meeting with FDA
admin
2019.10.25
39
HLB, Elevar agree to triangular merger deal to speed up Rivoceranib development
admin
2019.10.16
38
Rivoceranib named Best of ESMO 2019
admin
2019.10.02
37
Elevar announces results from the ANGEL trial
admin
2019.09.29